The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib) – which has ...
Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal ...
Background A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome. Objectives To describe clinical characteristics, laboratory findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results